A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer.

[1]  P. Schellhammer,et al.  Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. , 1995, The Journal of urology.

[2]  A. Harris,et al.  Different angiogenic pathways characterize superficial and invasive bladder cancer. , 1995, Cancer research.

[3]  E. Manseau,et al.  Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. , 1993, The American journal of pathology.

[4]  M. Benson,et al.  The predictive value of flow cytometry and urinary cytology in the followup of patients with transitional cell carcinoma of the bladder. , 1992, The Journal of urology.

[5]  Max H. Myers,et al.  Manual for Staging of Cancer , 1992 .

[6]  M. Melamed,et al.  Immunopathologic analysis of human urinary bladder cancer. Characterization of two new antigens associated with low-grade superficial bladder tumors. , 1992, The American journal of pathology.

[7]  H. Dvorak,et al.  Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. , 1989, Biochimica et biophysica acta.

[8]  L. Liotta,et al.  Detection of autocrine motility factor in urine as a marker of bladder cancer. , 1988, Journal of the National Cancer Institute.

[9]  G. Hemstreet,et al.  Cancer detection by quantitative fluorescence image analysis. , 1988, The Journal of urology.

[10]  M. Soloway,et al.  Flow cytometry versus urinary cytology in the evaluation of patients with bladder cancer. , 1986, The Journal of urology.

[11]  M. Hanna,et al.  A diagnostic-prognostic test for bladder cancer using a monoclonal antibody-based enzyme-linked immunoassay for detection of urinary fibrin(ogen) degradation products. , 1984, Cancer research.

[12]  H. Kim,et al.  The value of urinary fibrin/fibrinogen degradation products as tumor markers in urothelial carcinoma. , 1984, The Journal of urology.

[13]  E. Salzman.  Progress in Hemostasis and Thrombosis , 1981 .

[14]  G. Murphy,et al.  Further study of fibrinogen degradation products in bladder cancer detection. , 1978, Urology.

[15]  G. Murphy,et al.  Evaluation of biological markers in bladder cancer. , 1975, The Journal of urology.

[16]  B. M. Bennett,et al.  283. Note: On McNemar's Test for the 2 × 2 Table and Its Power Function , 1970 .

[17]  L. F. Greene,et al.  Study of five hundred patients with asymptomatic microhematuria. , 1956, Journal of the American Medical Association.

[18]  P. Armitage.  Tests for Linear Trends in Proportions and Frequencies , 1955 .

[19]  G. Roos,et al.  Value of DNA analysis for treatment of renal cell carcinoma. , 1990, European urology.

[20]  Marder Vj,et al.  The structure of the fibrinogen degradation products. , 1974 .